A Phase 2, proof-of-concept, 12-week, randomized, double-blind, placebo-controlled clinical trial with rosiptor (AQX-1125) in patients with chronic prostatitis/chronic Pelvic Pain Syndrome (CP/CPPS)
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Rosiptor (Primary)
- Indications Pelvic pain; Prostatitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Aquinox Pharmaceuticals
- 12 Mar 2018 According to an Aquinox Pharmaceuticals media release, the Company expects to initiate this trial in the second quarter of 2018.
- 11 Aug 2017 New trial record
- 08 Aug 2017 According to an Aquinox Pharmaceuticals media release, patient enrollment in this trial is expected to commence in the first quarter of 2018.